focu name trikafta launch pipelin progress
trikafta launch underway provid next leg cf growth particularli het/
min patient elig therapi vertex enter new
reimburs agreement french english author expand european
patient access therapi forecast cf sale grow billion
billion year billion result look non-gaap dilut
ep growth partner crispr
report addit data sever beta thalassemia sickl cell diseas patient
vertex expect report phase ii data phase data
pain year reiter overweight rate increas price target
roll forward price-to-earnings multipl non-gaap dilut ep
trikafta growth vertex launch trikafta treat homozyg
heterozyg cf patient expect rapid uptak het/min patient given
trikafta drug approv popul along use homozyg
patient respond well orkambi and/or symdeko vertex
file europ remain highli confid european approv
year new reimburs agreement could provid expand access vertex
therapi europ forecast cf sale grow billion
billion year billion
pipelin partnership increasingli import crispr report addit
potenti cur data sever beta thalassemia sickl cell diseas
patient partner expand allianc last june includ gene edit therapi
dmd vertex recent partner molecular templat employ
engin toxin bodi etb replac hsct pre-condit regimen safer
effect option patient vertex acquir semma cellular therapi treat
type diabet partner ribometrix discov novel rna-target small
molecul treat seriou diseas vertex expect report phase ii data
antitrypsin defici aatd initi phase ii studi focal
segment glomerulosclerosi fsg report phase data pain
increas price estim pro forma dilut ep grow
increas price
target roll forward price-to-earnings multipl pro forma
dilut ep discount roll forward
appli discount consist profit compani
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
discount
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
good sold
thousand except per share data
compani report piper sandler co analysi
current disclosur inform compani found
